Published in Am J Pathol on July 01, 1994
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet (1999) 4.16
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32
Morphology of sporadic colorectal cancer with DNA replication errors. Gut (1998) 3.11
Histopathological identification of colon cancer with microsatellite instability. Am J Pathol (2001) 2.90
High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol (1999) 2.80
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science (2017) 2.69
mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer (2007) 2.40
Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology (2007) 2.39
Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut (2005) 2.37
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol (2001) 2.29
Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol (2001) 2.13
Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut (2001) 2.08
Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol (2000) 2.03
Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol (2001) 1.95
Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol (2001) 1.79
DNA methylation in hepatocellular carcinoma. World J Gastroenterol (2008) 1.77
Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol (1997) 1.73
Colorectal cancer: genetics of development and metastasis. J Gastroenterol (2006) 1.63
HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer (2004) 1.60
Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A (2000) 1.55
Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol (1998) 1.55
Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol (2014) 1.48
Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol (2010) 1.47
Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer (2005) 1.47
Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol (2014) 1.44
Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg (1998) 1.42
Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol (1998) 1.42
Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut (2002) 1.38
Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol (2005) 1.36
Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol (1998) 1.36
Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction. J Mol Diagn (2000) 1.33
Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn (2006) 1.30
Screening for microsatellite instability target genes in colorectal cancers. J Med Genet (2002) 1.29
Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn (2011) 1.27
Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer (2005) 1.26
Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer. Gut (2000) 1.21
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2015) 1.19
Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol (2009) 1.17
Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract. Relation to clinicopathological data and family history. Am J Pathol (1995) 1.15
DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene (2012) 1.15
Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol (2009) 1.14
Genetic epidemiology of mutated K-ras proto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas. Gut (1999) 1.13
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis (2003) 1.07
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas. Am J Pathol (1997) 1.07
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis (2006) 1.06
Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol (1996) 1.06
Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status. J Clin Pathol (2006) 1.05
Tumor location is a prognostic factor in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon. Int J Colorectal Dis (2011) 1.04
Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer (2001) 1.04
Selective translational repression of truncated proteins from frameshift mutation-derived mRNAs in tumors. PLoS Biol (2007) 1.04
Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer (2001) 1.03
Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer (2013) 1.03
Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. Gut (2005) 1.02
Folate depletion impairs DNA excision repair in the colon of the rat. Gut (1998) 1.02
Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch (2007) 1.00
The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol (1998) 1.00
Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer (2002) 1.00
Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer (2015) 1.00
The role of microsatellite instability in gastric carcinoma. Gut (1998) 0.99
Animal models of colorectal cancer. Cancer Metastasis Rev (2013) 0.99
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer (2010) 0.98
An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. Cancer Res (2009) 0.97
Serrated neoplasia of the colorectum. World J Gastroenterol (2007) 0.97
Infrequent microsatellite instability in oesophageal cancers. Br J Cancer (1997) 0.97
Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray study. J Clin Pathol (2003) 0.97
Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int J Colorectal Dis (2004) 0.96
Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Fam Cancer (2004) 0.96
Functional significance of concomitant inactivation of hMLH1 and hMSH6 in tumor cells of the microsatellite mutator phenotype. Proc Natl Acad Sci U S A (2001) 0.96
Microsatellite instability, Epstein-Barr virus, mutation of type II transforming growth factor beta receptor and BAX in gastric carcinomas in Hong Kong Chinese. Br J Cancer (1999) 0.95
The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis (2006) 0.94
K-ras mutations and HLA-DR expression in large bowel adenomas. Br J Cancer (1996) 0.94
Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location. Virchows Arch (2006) 0.93
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J (2014) 0.90
Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects. Dig Dis Sci (2008) 0.90
Biomarkers predicting development of metachronous gastric cancer after endoscopic resection: an analysis of molecular pathology of Helicobacter pylori eradication. Int J Cancer (2011) 0.90
What we could do now: molecular pathology of colorectal cancer. Mol Pathol (2001) 0.88
Clinicopathologic features and prognostic analysis of MSI-high colon cancer. Int J Colorectal Dis (2011) 0.88
Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Arch (2014) 0.87
Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours. Br J Cancer (1999) 0.87
Towards a vaccine to prevent cancer in Lynch syndrome patients. Fam Cancer (2013) 0.86
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects. Am J Pathol (2001) 0.86
Villin expression is frequently lost in poorly differentiated colon cancer. Am J Pathol (2012) 0.86
Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget (2015) 0.85
Development and progression of colorectal neoplasia. Cancer Biomark (2010) 0.85
CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Chemother Res Pract (2012) 0.85
Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with variable tumour morphology and immunohistochemical expression. J Clin Pathol (2006) 0.85
Extracolonic features of familial adenomatous polyposis in patients with sporadic colorectal cancer. Br J Cancer (1996) 0.85
Bcl-2 expression in colorectal tumors: evidence of different pathways in sporadic and ulcerative-colitis-associated carcinomas. Am J Pathol (1996) 0.85
Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma. Indian J Med Res (2011) 0.84
Clinicopathological analysis of colorectal cancer: a comparison between emergency and elective surgical cases. World J Surg Oncol (2013) 0.84
Is mucinous carcinoma of the colorectum a distinct genetic entity? Br J Cancer (1995) 0.83
Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer. Genes Chromosomes Cancer (2011) 0.83
DNA fingerprinting techniques for the analysis of genetic and epigenetic alterations in colorectal cancer. Mutat Res (2010) 0.83
Molecular pathogenesis of sporadic duodenal cancer. Br J Cancer (1998) 0.83
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Microsatellite instability in cancer of the proximal colon. Science (1993) 14.51
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1993) 13.54
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (1993) 12.74
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature (1993) 10.95
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
p53 function and dysfunction. Cell (1992) 7.73
Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell (1993) 6.61
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science (1991) 6.15
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res (1993) 4.93
Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med (1990) 4.23
Genetic mapping of a locus predisposing to human colorectal cancer. Science (1993) 4.12
Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology (1993) 3.76
A new prognostic classification of rectal cancer. Lancet (1987) 3.56
An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol (1994) 2.67
Nucleotide repeats. Slippery DNA and diseases. Nature (1993) 2.56
Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet (1993) 2.37
pp60c-src activation in human colon carcinoma. J Clin Invest (1989) 2.07
Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol (1993) 1.91
p53: the ultimate tumor suppressor gene? FASEB J (1992) 1.85
Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol (1990) 1.83
Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci U S A (1992) 1.74
A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer (1988) 1.72
The p53 tumor-suppressor gene. N Engl J Med (1992) 1.27
Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum (1986) 1.11
Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology (1987) 1.07
Oncogene alterations in primary human colon tumors. Gastroenterology (1986) 0.97
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
"A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem (1984) 66.58
Serial analysis of gene expression. Science (1995) 60.15
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Surfing the p53 network. Nature (2000) 35.36
p53 mutations in human cancers. Science (1991) 31.96
Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci U S A (1979) 27.20
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Genetic instabilities in human cancers. Nature (1998) 22.76
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
Genetic instability in colorectal cancers. Nature (1997) 12.51
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
A model for p53-induced apoptosis. Nature (1997) 11.38
Characterization of the yeast transcriptome. Cell (1997) 11.33
Mutations of mitotic checkpoint genes in human cancers. Nature (1998) 11.20
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Genes expressed in human tumor endothelium. Science (2000) 10.75
Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (1992) 10.12
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
A public database for gene expression in human cancers. Cancer Res (1999) 8.81
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell (2001) 7.95
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 7.20
Association of the APC tumor suppressor protein with catenins. Science (1993) 7.17
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res (1995) 6.66
The molecular basis of Turcot's syndrome. N Engl J Med (1995) 6.65
Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell (1993) 6.61
Identification of p53 as a sequence-specific DNA-binding protein. Science (1991) 6.60
Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A (1992) 6.58
Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun (1985) 6.57
Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet (2001) 6.36
Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science (1991) 6.15
Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest (1999) 6.13
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (1996) 6.11
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res (1999) 6.10
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
Cancer-susceptibility genes. Gatekeepers and caretakers. Nature (1997) 5.87
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res (1998) 5.80
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res (1990) 5.70
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 5.68
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst (1997) 5.68
p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev (1995) 5.63
Allelotype of colorectal carcinomas. Science (1989) 5.54
14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature (1999) 5.44
Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res (1995) 5.26
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20
Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med (1994) 5.12
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 5.12
Role of BAX in the apoptotic response to anticancer agents. Science (2000) 5.07
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med (1996) 4.87
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet (1998) 4.67
The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med (1997) 4.66
Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med (1987) 4.55
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet (1997) 4.46
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A (2000) 4.37
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32
Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res (1987) 4.25